- Home
- LOCO vs LRMR Comparison
LOCO vs LRMR Comparison
Compare LOCO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- LRMR
- Stock Information
- Founded
- LOCO 1980
- LRMR N/A
- Country
- LOCO United States
- LRMR United States
- Employees
- LOCO N/A
- LRMR N/A
- Industry
- LOCO Restaurants
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- LRMR Health Care
- Exchange
- LOCO Nasdaq
- LRMR Nasdaq
- Market Cap
- LOCO 412.4M
- LRMR 426.9M
- IPO Year
- LOCO 2014
- LRMR N/A
- Fundamental
- Price
- LOCO $11.63
- LRMR $4.01
- Analyst Decision
- LOCO Hold
- LRMR Strong Buy
- Analyst Count
- LOCO 2
- LRMR 8
- Target Price
- LOCO $13.00
- LRMR $19.63
- AVG Volume (30 Days)
- LOCO 210.4K
- LRMR 1.1M
- Earning Date
- LOCO 10-31-2024
- LRMR 10-30-2024
- Dividend Yield
- LOCO N/A
- LRMR N/A
- EPS Growth
- LOCO 0.40
- LRMR N/A
- EPS
- LOCO 0.78
- LRMR N/A
- Revenue
- LOCO $470,971,000.00
- LRMR N/A
- Revenue This Year
- LOCO $2.72
- LRMR N/A
- Revenue Next Year
- LOCO $3.75
- LRMR N/A
- P/E Ratio
- LOCO $14.87
- LRMR N/A
- Revenue Growth
- LOCO N/A
- LRMR N/A
- 52 Week Low
- LOCO $8.17
- LRMR $3.01
- 52 Week High
- LOCO $14.25
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- LOCO 38.10
- LRMR 25.50
- Support Level
- LOCO $11.54
- LRMR $3.83
- Resistance Level
- LOCO $13.14
- LRMR $6.91
- Average True Range (ATR)
- LOCO 0.40
- LRMR 0.57
- MACD
- LOCO -0.07
- LRMR -0.22
- Stochastic Oscillator
- LOCO 6.79
- LRMR 25.64
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.